A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) in Dravet Syndrome, Lennox Gastaut Syndrome and Epileptic Encephalopathy, sponsored by Zogenix, Inc.. Completed at 71 sites in 14 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one has the largest enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 6th registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 16+
University of Colorado, Denver · Sites in United States
Ages 12 mo–24 mo
By country, each count listing its studies:
Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2019.
This study's enrollment of 412 is above the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 25 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
This study is registered under Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
UCB S.A. has 8 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
2 of the studies testing fenfluramine in Epilepsies, Myoclonic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06598449University of Colorado, DenverAssessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age | 2026-12 |
| NCT07112365The University of Texas Health Science Center, HoustonThe FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
This is an international, multicenter, open-label, long-term safety study of ZX008 in patients with epileptic encephalopathy, including Dravet syndrome or Lennox-Gastaut syndrome. Subjects eligible for participation are those with Dravet syndrome who are currently enrolled in Study ZX008-1503, or those with Lennox-Gastaut syndrome who have successfully completed Study ZX008-1601-Part 2, and are candidates for continued treatment with ZX008 for an extended period of time, or those with Dravet syndrome, Lennox-Gastaut syndrome, or another epileptic encephalopathy who have completed participation in another Zogenix-sponsored study and have been invited to participate in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZX008 is supplied as an open-label oral solution.Doses will include up to 0.8 mg/kg/day divided into 2 daily doses, up to a maximum of 30 mg/day (subjects taking concomitant STP will receive up to 0.5 mg/kg/day, up to a maximum of 20 mg/day) in a concentration of 2.5 mg/mL.
Drug: ZX008 (Fenfluramine Hydrochloride)
Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs were defined as AE that began on or after the first day of treatment with ZX008 in Study EP0215 (ZX008-1900) (NCT03936777) or that occurred prior to first ZX008 treatment in Study EP0215 (ZX008-1900) but increased in severity after treatment in Study EP0215 (ZX008-1900) began. Events recorded at Follow-up/Cardiac Follow-up were considered treatment-emergent. The percentage of participants was rounded to one decimal place.
Time frame: From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days)
Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Parent/Caregiver
The Clinical Global Impression-Improvement (CGI-I) scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Global: Assessment by Investigator
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Parent/Caregiver
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Parent/Caregiver
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Motor Abilities: Assessment by Parent/Caregiver
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Cognition: Assessment by Investigator
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression-Improvement in Participants, Subscale Behavior: Assessment by Investigator
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Clinical Global Impression Improvement in Participants, Subscale Motor Abilities: Assessment by Investigator
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
Time frame: Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
Number of Participants With Improvement in Seizure Burden as Assessed by the Investigator
The change in seizure burden from the previous visit was assessed by the investigator using following categories: \<25%, ≥25%, ≥50%, ≥75%, 100% (i.e., seizure-free) improvement. Improvement in seizure burden at Baseline was based on comparison with the participant's last visit in the feeder studies (ZX008-1601, ZX008-1503, and ZX008-1602). Number of participants in each of the 5 categories is reported for each visit as compared to last visit.
Time frame: Baseline (Day 1), Months 6, 12, 18, 24, 30, 36, Last On-Treatment Visit (Up to Month 49)
The study started to enroll participants in April 2019 and concluded in May 2025.
| Milestone | Any ZX008 Open Label Dose |
|---|---|
| Started | 412 |
| Completed | 360 |
| Not completed | 52 |
| Withdrew: Adverse event | 3 |
| Withdrew: Death | 3 |
| Withdrew: Lack of efficacy | 24 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Subjected weaned of zx008 | 1 |
| Withdrew: Missing | 6 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. TEAEs were defined as AE that began on or after the first day of treatment with ZX008 in Study EP0215 (ZX008-1900) (NCT03936777) or that occurred prior to first ZX008 treatment in Study EP0215 (ZX008-1900) but increased in severity after treatment in Study EP0215 (ZX008-1900) began. Events recorded at Follow-up/Cardiac Follow-up were considered treatment-emergent. The percentage of participants was rounded to one decimal place.
| percentage of participants | Any ZX008 Open Label Dose |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 75.5 |
The Clinical Global Impression-Improvement (CGI-I) scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 39 |
| Month 6: Much improved | 88 |
| Month 6: Minimally improved | 87 |
| Month 6: No change | 124 |
| Month 6: Minimally worse | 23 |
| Month 6: Much worse | 7 |
| Month 6: Very much worse | 3 |
| Month 12: Very much improved | 42 |
| Month 12: Much improved | 65 |
| Month 12: Minimally improved | 56 |
| Month 12: No change | 77 |
| Month 12: Minimally worse | 17 |
| Month 12: Much worse | 9 |
| Month 12: Very much worse | 0 |
| Month 18: Very much improved | 34 |
| Month 18: Much improved | 43 |
| Month 18: Minimally improved | 60 |
| Month 18: No change | 67 |
| Month 18: Minimally worse | 16 |
| Month 18: Much worse | 2 |
| Month 18: Very much worse | 1 |
| Month 24: Very much improved | 33 |
| Month 24: Much improved | 46 |
| Month 24: Minimally improved | 41 |
| Month 24: No change | 59 |
| Month 24: Minimally worse | 8 |
| Month 24: Much worse | 1 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 16 |
| Month 30: Much improved | 41 |
| Month 30: Minimally improved | 34 |
| Month 30: No change | 47 |
| Month 30: Minimally worse | 9 |
| Month 30: Much worse | 1 |
| Month 30: Very much worse | 1 |
| Month 36: Very much improved | 16 |
| Month 36: Much improved | 31 |
| Month 36: Minimally improved | 29 |
| Month 36: No change | 39 |
| Month 36: Minimally worse | 10 |
| Month 36: Much worse | 3 |
| Month 36: Very much worse | 0 |
| Last On-Treatment Visit: Very much improved | 71 |
| Last On-Treatment Visit: Much improved | 109 |
| Last On-Treatment Visit: Minimally improved | 85 |
| Last On-Treatment Visit: No change | 108 |
| Last On-Treatment Visit: Minimally worse | 21 |
| Last On-Treatment Visit: Much worse | 7 |
| Last On-Treatment Visit: Very much worse | 0 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Global function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The global CGI-I assessment was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 23 |
| Month 6: Much improved | 86 |
| Month 6: Minimally improved | 85 |
| Month 6: No change | 141 |
| Month 6: Minimally worse | 26 |
| Month 6: Much worse | 4 |
| Month 6: Very much worse | 2 |
| Month 12: Very much improved | 28 |
| Month 12: Much improved | 63 |
| Month 12: Minimally improved | 66 |
| Month 12: No change | 87 |
| Month 12: Minimally worse | 17 |
| Month 12: Much worse | 3 |
| Month 12: Very much worse | 1 |
| Month 18: Very much improved | 23 |
| Month 18: Much improved | 45 |
| Month 18: Minimally improved | 58 |
| Month 18: No change | 86 |
| Month 18: Minimally worse | 12 |
| Month 18: Much worse | 1 |
| Month 18: Very much worse | 0 |
| Month 24: Very much improved | 20 |
| Month 24: Much improved | 54 |
| Month 24: Minimally improved | 37 |
| Month 24: No change | 72 |
| Month 24: Minimally worse | 5 |
| Month 24: Much worse | 1 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 11 |
| Month 30: Much improved | 44 |
| Month 30: Minimally improved | 34 |
| Month 30: No change | 56 |
| Month 30: Minimally worse | 3 |
| Month 30: Much worse | 1 |
| Month 30: Very much worse | 0 |
| Month 36: Very much improved | 7 |
| Month 36: Much improved | 33 |
| Month 36: Minimally improved | 25 |
| Month 36: No change | 52 |
| Month 36: Minimally worse | 5 |
| Month 36: Much worse | 2 |
| Month 36: Very much worse | 0 |
| Last On-Treatment Visit: Very much improved | 33 |
| Last On-Treatment Visit: Much improved | 108 |
| Last On-Treatment Visit: Minimally improved | 101 |
| Last On-Treatment Visit: No change | 134 |
| Last On-Treatment Visit: Minimally worse | 19 |
| Last On-Treatment Visit: Much worse | 5 |
| Last On-Treatment Visit: Very much worse | 1 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 26 (4.6 to 10.1) |
| Month 6: Much improved | 75 (16.3 to 24.7) |
| Month 6: Minimally improved | 87 (19.3 to 28.2) |
| Month 6: No change | 161 (38.4 to 48.7) |
| Month 6: Minimally worse | 15 (2.3 to 6.6) |
| Month 6: Much worse | 4 (0.3 to 2.7) |
| Month 6: Very much worse | 2 (0.1 to 1.9) |
| Month 12: Very much improved | 17 (3.8 to 10.1) |
| Month 12: Much improved | 54 (15.7 to 25.7) |
| Month 12: Minimally improved | 78 (24.0 to 35.3) |
| Month 12: No change | 108 (34.8 to 46.9) |
| Month 12: Minimally worse | 5 (0.6 to 4.3) |
| Month 12: Much worse | 3 (0.2 to 3.3) |
| Month 12: Very much worse | 0 (0 to 1.4) |
| Month 18: Very much improved | 18 (4.8 to 12.4) |
| Month 18: Much improved | 43 (14.3 to 25.0) |
| Month 18: Minimally improved | 69 (24.8 to 37.3) |
| Month 18: No change | 86 (32.0 to 45.1) |
| Month 18: Minimally worse | 6 (1.0 to 5.7) |
| Month 18: Much worse | 2 (0.1 to 3.2) |
| Month 18: Very much worse | 0 (0 to 1.6) |
| Month 24: Very much improved | 14 (4.1 to 12.2) |
| Month 24: Much improved | 35 (13.3 to 24.9) |
| Month 24: Minimally improved | 59 (24.8 to 38.5) |
| Month 24: No change | 73 (31.8 to 46.2) |
| Month 24: Minimally worse | 6 (1.2 to 6.8) |
| Month 24: Much worse | 1 (0.0 to 2.9) |
| Month 24: Very much worse | 0 (0 to 1.9) |
| Month 30: Very much improved | 7 (1.9 to 9.4) |
| Month 30: Much improved | 31 (14.6 to 28.2) |
| Month 30: Minimally improved | 41 (20.5 to 35.4) |
| Month 30: No change | 62 (33.6 to 50.0) |
| Month 30: Minimally worse | 6 (1.5 to 8.6) |
| Month 30: Much worse | 1 (0.0 to 3.7) |
| Month 30: Very much worse | 1 (0.0 to 3.7) |
| Month 36: Very much improved | 6 (1.7 to 9.9) |
| Month 36: Much improved | 32 (17.8 to 33.4) |
| Month 36: Minimally improved | 29 (15.7 to 30.9) |
| Month 36: No change | 49 (29.8 to 47.3) |
| Month 36: Minimally worse | 11 (4.4 to 14.9) |
| Month 36: Much worse | 1 (0.0 to 4.3) |
| Month 36: Very much worse | 0 (0 to 2.8) |
| Last On-Treatment Visit: Very much improved | 33 (5.7 to 11.4) |
| Last On-Treatment Visit: Much improved | 98 (20.3 to 28.9) |
| Last On-Treatment Visit: Minimally improved | 101 (21.0 to 29.7) |
| Last On-Treatment Visit: No change | 148 (32.2 to 41.8) |
| Last On-Treatment Visit: Minimally worse | 16 (2.3 to 6.4) |
| Last On-Treatment Visit: Much worse | 5 (0.4 to 2.9) |
| Last On-Treatment Visit: Very much worse | 0 (0 to 0.9) |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 20 |
| Month 6: Much improved | 51 |
| Month 6: Minimally improved | 75 |
| Month 6: No change | 174 |
| Month 6: Minimally worse | 35 |
| Month 6: Much worse | 12 |
| Month 6: Very much worse | 3 |
| Month 12: Very much improved | 9 |
| Month 12: Much improved | 46 |
| Month 12: Minimally improved | 51 |
| Month 12: No change | 120 |
| Month 12: Minimally worse | 28 |
| Month 12: Much worse | 11 |
| Month 12: Very much worse | 0 |
| Month 18: Very much improved | 13 |
| Month 18: Much improved | 37 |
| Month 18: Minimally improved | 42 |
| Month 18: No change | 100 |
| Month 18: Minimally worse | 27 |
| Month 18: Much worse | 4 |
| Month 18: Very much worse | 1 |
| Month 24: Very much improved | 13 |
| Month 24: Much improved | 31 |
| Month 24: Minimally improved | 36 |
| Month 24: No change | 83 |
| Month 24: Minimally worse | 16 |
| Month 24: Much worse | 9 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 8 |
| Month 30: Much improved | 26 |
| Month 30: Minimally improved | 27 |
| Month 30: No change | 69 |
| Month 30: Minimally worse | 15 |
| Month 30: Much worse | 4 |
| Month 30: Very much worse | 0 |
| Month 36: Very much improved | 7 |
| Month 36: Much improved | 18 |
| Month 36: Minimally improved | 28 |
| Month 36: No change | 58 |
| Month 36: Minimally worse | 10 |
| Month 36: Much worse | 6 |
| Month 36: Very much worse | 1 |
| Last On-Treatment Visit: Very much improved | 24 |
| Last On-Treatment Visit: Much improved | 73 |
| Last On-Treatment Visit: Minimally improved | 83 |
| Last On-Treatment Visit: No change | 169 |
| Last On-Treatment Visit: Minimally worse | 36 |
| Last On-Treatment Visit: Much worse | 15 |
| Last On-Treatment Visit: Very much worse | 1 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Parent/Caregiver. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 17 |
| Month 6: Much improved | 45 |
| Month 6: Minimally improved | 86 |
| Month 6: No change | 190 |
| Month 6: Minimally worse | 26 |
| Month 6: Much worse | 4 |
| Month 6: Very much worse | 2 |
| Month 12: Very much improved | 14 |
| Month 12: Much improved | 31 |
| Month 12: Minimally improved | 65 |
| Month 12: No change | 134 |
| Month 12: Minimally worse | 14 |
| Month 12: Much worse | 6 |
| Month 12: Very much worse | 1 |
| Month 18: Very much improved | 10 |
| Month 18: Much improved | 31 |
| Month 18: Minimally improved | 48 |
| Month 18: No change | 114 |
| Month 18: Minimally worse | 16 |
| Month 18: Much worse | 4 |
| Month 18: Very much worse | 1 |
| Month 24: Very much improved | 16 |
| Month 24: Much improved | 19 |
| Month 24: Minimally improved | 42 |
| Month 24: No change | 97 |
| Month 24: Minimally worse | 13 |
| Month 24: Much worse | 1 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 7 |
| Month 30: Much improved | 22 |
| Month 30: Minimally improved | 27 |
| Month 30: No change | 77 |
| Month 30: Minimally worse | 13 |
| Month 30: Much worse | 2 |
| Month 30: Very much worse | 1 |
| Month 36: Very much improved | 6 |
| Month 36: Much improved | 16 |
| Month 36: Minimally improved | 22 |
| Month 36: No change | 67 |
| Month 36: Minimally worse | 9 |
| Month 36: Much worse | 7 |
| Month 36: Very much worse | 1 |
| Last On-Treatment Visit: Very much improved | 24 |
| Last On-Treatment Visit: Much improved | 55 |
| Last On-Treatment Visit: Minimally improved | 94 |
| Last On-Treatment Visit: No change | 191 |
| Last On-Treatment Visit: Minimally worse | 25 |
| Last On-Treatment Visit: Much worse | 12 |
| Last On-Treatment Visit: Very much worse | 0 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Cognitive function is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of cognition was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 13 |
| Month 6: Much improved | 54 |
| Month 6: Minimally improved | 101 |
| Month 6: No change | 184 |
| Month 6: Minimally worse | 9 |
| Month 6: Much worse | 2 |
| Month 6: Very much worse | 2 |
| Month 12: Very much improved | 13 |
| Month 12: Much improved | 39 |
| Month 12: Minimally improved | 79 |
| Month 12: No change | 128 |
| Month 12: Minimally worse | 4 |
| Month 12: Much worse | 1 |
| Month 12: Very much worse | 1 |
| Month 18: Very much improved | 13 |
| Month 18: Much improved | 32 |
| Month 18: Minimally improved | 53 |
| Month 18: No change | 118 |
| Month 18: Minimally worse | 10 |
| Month 18: Much worse | 0 |
| Month 18: Very much worse | 0 |
| Month 24: Very much improved | 9 |
| Month 24: Much improved | 33 |
| Month 24: Minimally improved | 55 |
| Month 24: No change | 88 |
| Month 24: Minimally worse | 3 |
| Month 24: Much worse | 1 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 4 |
| Month 30: Much improved | 25 |
| Month 30: Minimally improved | 36 |
| Month 30: No change | 81 |
| Month 30: Minimally worse | 3 |
| Month 30: Much worse | 0 |
| Month 30: Very much worse | 0 |
| Month 36: Very much improved | 4 |
| Month 36: Much improved | 14 |
| Month 36: Minimally improved | 34 |
| Month 36: No change | 65 |
| Month 36: Minimally worse | 7 |
| Month 36: Much worse | 0 |
| Month 36: Very much worse | 0 |
| Last On-Treatment Visit: Very much improved | 16 |
| Last On-Treatment Visit: Much improved | 64 |
| Last On-Treatment Visit: Minimally improved | 103 |
| Last On-Treatment Visit: No change | 201 |
| Last On-Treatment Visit: Minimally worse | 12 |
| Last On-Treatment Visit: Much worse | 1 |
| Last On-Treatment Visit: Very much worse | 2 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Behavior is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of behavior was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 10 |
| Month 6: Much improved | 42 |
| Month 6: Minimally improved | 80 |
| Month 6: No change | 200 |
| Month 6: Minimally worse | 27 |
| Month 6: Much worse | 5 |
| Month 6: Very much worse | 1 |
| Month 12: Very much improved | 11 |
| Month 12: Much improved | 35 |
| Month 12: Minimally improved | 54 |
| Month 12: No change | 144 |
| Month 12: Minimally worse | 17 |
| Month 12: Much worse | 3 |
| Month 12: Very much worse | 1 |
| Month 18: Very much improved | 7 |
| Month 18: Much improved | 32 |
| Month 18: Minimally improved | 41 |
| Month 18: No change | 122 |
| Month 18: Minimally worse | 20 |
| Month 18: Much worse | 3 |
| Month 18: Very much worse | 1 |
| Month 24: Very much improved | 11 |
| Month 24: Much improved | 28 |
| Month 24: Minimally improved | 36 |
| Month 24: No change | 95 |
| Month 24: Minimally worse | 17 |
| Month 24: Much worse | 2 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 2 |
| Month 30: Much improved | 28 |
| Month 30: Minimally improved | 25 |
| Month 30: No change | 77 |
| Month 30: Minimally worse | 15 |
| Month 30: Much worse | 2 |
| Month 30: Very much worse | 0 |
| Month 36: Very much improved | 1 |
| Month 36: Much improved | 19 |
| Month 36: Minimally improved | 28 |
| Month 36: No change | 63 |
| Month 36: Minimally worse | 11 |
| Month 36: Much worse | 2 |
| Month 36: Very much worse | 0 |
| Last On-Treatment Visit: Very much improved | 14 |
| Last On-Treatment Visit: Much improved | 57 |
| Last On-Treatment Visit: Minimally improved | 74 |
| Last On-Treatment Visit: No change | 229 |
| Last On-Treatment Visit: Minimally worse | 20 |
| Last On-Treatment Visit: Much worse | 3 |
| Last On-Treatment Visit: Very much worse | 2 |
The CGI-I scale is used to assess the severity of illness and global improvement in patients. Motor abilities is one of the domains assessed by the CGI-I scale. The CGI-I is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=Very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse, where higher score indicates worse outcome. The CGI-I assessment of motor abilities was conducted by the Investigator. The number of participants in each of the 7 categories of the CGI-I for each visit is reported.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Month 6: Very much improved | 10 |
| Month 6: Much improved | 33 |
| Month 6: Minimally improved | 81 |
| Month 6: No change | 221 |
| Month 6: Minimally worse | 17 |
| Month 6: Much worse | 1 |
| Month 6: Very much worse | 2 |
| Month 12: Very much improved | 13 |
| Month 12: Much improved | 29 |
| Month 12: Minimally improved | 52 |
| Month 12: No change | 159 |
| Month 12: Minimally worse | 10 |
| Month 12: Much worse | 0 |
| Month 12: Very much worse | 2 |
| Month 18: Very much improved | 9 |
| Month 18: Much improved | 19 |
| Month 18: Minimally improved | 42 |
| Month 18: No change | 133 |
| Month 18: Minimally worse | 21 |
| Month 18: Much worse | 2 |
| Month 18: Very much worse | 0 |
| Month 24: Very much improved | 7 |
| Month 24: Much improved | 24 |
| Month 24: Minimally improved | 43 |
| Month 24: No change | 99 |
| Month 24: Minimally worse | 13 |
| Month 24: Much worse | 3 |
| Month 24: Very much worse | 0 |
| Month 30: Very much improved | 4 |
| Month 30: Much improved | 19 |
| Month 30: Minimally improved | 29 |
| Month 30: No change | 86 |
| Month 30: Minimally worse | 9 |
| Month 30: Much worse | 1 |
| Month 30: Very much worse | 1 |
| Month 36: Very much improved | 2 |
| Month 36: Much improved | 9 |
| Month 36: Minimally improved | 27 |
| Month 36: No change | 74 |
| Month 36: Minimally worse | 8 |
| Month 36: Much worse | 4 |
| Month 36: Very much worse | 0 |
| Last On-Treatment Visit: Very much improved | 12 |
| Last On-Treatment Visit: Much improved | 39 |
| Last On-Treatment Visit: Minimally improved | 89 |
| Last On-Treatment Visit: No change | 238 |
| Last On-Treatment Visit: Minimally worse | 16 |
| Last On-Treatment Visit: Much worse | 4 |
| Last On-Treatment Visit: Very much worse | 1 |
The change in seizure burden from the previous visit was assessed by the investigator using following categories: \<25%, ≥25%, ≥50%, ≥75%, 100% (i.e., seizure-free) improvement. Improvement in seizure burden at Baseline was based on comparison with the participant's last visit in the feeder studies (ZX008-1601, ZX008-1503, and ZX008-1602). Number of participants in each of the 5 categories is reported for each visit as compared to last visit.
| Participants | Any ZX008 Open Label Dose |
|---|---|
| Baseline: <25% | 242 |
| Baseline: >=25% | 67 |
| Baseline: >=50% | 42 |
| Baseline: >=75% | 35 |
| Baseline: 100% | 12 |
| Month 6: <25% | 262 |
| Month 6: >=25% | 51 |
| Month 6: >=50% | 39 |
| Month 6: >=75% | 21 |
| Month 6: 100% | 8 |
| Month 12: <25% | 191 |
| Month 12: >=25% | 33 |
| Month 12: >=50% | 31 |
| Month 12: >=75% | 11 |
| Month 12: 100% | 6 |
| Month 18: <25% | 175 |
| Month 18: >=25% | 22 |
| Month 18: >=50% | 26 |
| Month 18: >=75% | 3 |
| Month 18: 100% | 6 |
| Month 24: <25% | 144 |
| Month 24: >=25% | 24 |
| Month 24: >=50% | 15 |
| Month 24: >=75% | 6 |
| Month 24: 100% | 4 |
| Month 30: <25% | 115 |
| Month 30: >=25% | 14 |
| Month 30: >=50% | 11 |
| Month 30: >=75% | 7 |
| Month 30: 100% | 1 |
| Month 36: <25% | 99 |
| Month 36: >=25% | 13 |
| Month 36: >=50% | 9 |
| Month 36: >=75% | 6 |
| Month 36: 100% | 1 |
| Last On-Treatment Visit: <25% | 315 |
| Last On-Treatment Visit: >=25% | 41 |
| Last On-Treatment Visit: >=50% | 29 |
| Last On-Treatment Visit: >=75% | 17 |
| Last On-Treatment Visit: 100% | 8 |
Collected over From First dose of ZX008 (in study EP0215 [ZX008-1900]) to Cardiac Follow-up after ZX008 treatment (Up to 6 Years, 17 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any ZX008 Open Label Dose | 3/412 (0.7%) | 67/412 (16.3%) | 204/412 (49.5%) |
| Event | Any ZX008 Open Label Dose |
|---|---|
| SeizureNervous system disorders | 17/412 |
| Status epilepticusNervous system disorders | 9/412 |
| PneumoniaInfections and infestations | 8/412 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 5/412 |
| DehydrationMetabolism and nutrition disorders | 3/412 |
| AstheniaGeneral disorders | 2/412 |
| AppendicitisInfections and infestations | 2/412 |
| Corona virus infectionInfections and infestations | 2/412 |
| Pneumonia viralInfections and infestations | 2/412 |
| Urinary tract infectionInfections and infestations | 2/412 |
| Event | Any ZX008 Open Label Dose |
|---|---|
| Corona virus infectionInfections and infestations | 84/412 |
| PyrexiaGeneral disorders | 53/412 |
| SeizureNervous system disorders | 52/412 |
| NasopharyngitisInfections and infestations | 49/412 |
| DiarrhoeaGastrointestinal disorders | 29/412 |
| Decreased appetiteMetabolism and nutrition disorders | 25/412 |
| Upper respiratory tract infectionInfections and infestations | 23/412 |
Baseline Characteristics refer to the Safety analysis set which consisted of all participants who received at least one dose of ZX008 during the open label extension (OLE).
| Age, Continuous(Years) | Any ZX008 Open Label Dose |
|---|---|
| Mean | 14.1 ± 6.8 |
| Age, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| 2 - <12 years | 168 |
| 12 - <18 years | 117 |
| 18 - <65 years | 127 |
| Sex: Female, Male(Participants) | Any ZX008 Open Label Dose |
|---|---|
| Female | 191 |
| Male | 221 |
| Race/Ethnicity, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 19 |
| Black or African American | 11 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 327 |
| Other or Mixed | 4 |
| Not Reported | 35 |
| Unknown | 11 |
| Race/Ethnicity, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| Hispanic or Latino | 60 |
| Not Hispanic or Latino | 303 |
| Not Reported | 42 |
| Unknown | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Apr 2019 to primary completion in May 2025, 72 months.
Results were first posted in Nov 2025, 6 months after primary completion.
Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 72 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine